The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma
The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma
复制标题
DOI：
10.1093/annonc/mdx699
复制
发表时间：
2018-02-01
影响因子：
50.5
通讯作者：
Birnbaum, D.
中科院分区：
文献类型：
--
作者：
Bertucci, F.;De Nonneville, A.;Birnbaum, D.
Background: Soft-tissue sarcomas (STSs) are a group of rare, heterogeneous, and aggressive tumors, with high metastatic risk and relatively few efficient systemic therapies. We hypothesized that the Genomic Grade Index (GGI), a 108-gene signature previously developed in early-stage breast cancer, might improve the prognostic assessment of patients with early-stage STS.Patients and methods: We collected gene expression and clinicopathological data of 678 operated STS, and searched for correlations between the GGI-based classification and clinicopathological variables, including the metastasis-free survival (MFS).Results: Based on GGI, 275 samples (41%) were classified as 'GGI-low' and 403 (59%) as 'GGI-high'. The 'GGI-high' class was more associated with poor-prognosis features than the ` GGI-low' class: pathological grade 3 (P = 9.50E-11), undifferentiated sarcomas and leiomyosarcomas (P
